Clinical Trial Update: Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nivolumab in bladder cancer patients previously treated with intravesical BCG was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Bladder Cancer | Phase 1 | Status: TERMINATED